Sei Investments CO Affimed N.V. Transaction History

Sei Investments CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.66 - $1.29 $1,601 - $3,129	-2,426 Reduced 5.8%	39,415 $29,000
Q4 2022 Feb 10, 2023	BUY	$1.1 - $2.45 $46,025 - $102,510	41,841 New	41,841 $51,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $581,062 - $787,686	-104,885 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$7.78 - $11.4 $816,005 - $1.2 Million	104,885 New	104,885 $892,000
Q3 2020 Nov 06, 2020	SELL	$3.26 - $4.73 $43,361 - $62,913	-13,301 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$1.58 - $4.63 $29,974 - $87,835	-18,971 Reduced 58.78%	13,301 $61,000
Q2 2020 Aug 11, 2020	BUY	$1.58 - $4.63 $361 - $1,060	229 Added 0.71%	32,272 $89,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $83,311 - $134,901	32,043 New	32,043 $92,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.